Journal of diabetes and its complications最新文献

{"title":"Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials","authors":"Amparo Ortiz-Seller ,&nbsp;José Tomás Real ,&nbsp;Esteban Morcillo ,&nbsp;José Luis Ortiz","doi":"10.1016/j.jdiacomp.2025.109234","DOIUrl":"10.1016/j.jdiacomp.2025.109234","url":null,"abstract":"<div><h3>Aims</h3><div>To update evidence on the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitors and incident diabetic retinopathy (DR) in type 2 diabetes.</div></div><div><h3>Methods</h3><div>We searched Embase, PubMed, Web of Science, and <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (to July 2025) for randomized controlled trials (RCTs) and pooled odds ratios (ORs) with 95 % credible intervals (CrIs) using a Bayesian network meta-analysis. Network meta-regression assessed estimated effect modification; a model-based network meta-analysis (MBNMAdose) evaluated dose–response. Evidence certainty was appraised with Confidence in Network Meta-Analysis (CINeMA).</div></div><div><h3>Results</h3><div>Forty-three trials (74,546 participants; 779 DR events) were analyzed. No DPP-4 inhibitor significantly changed the DR risk versus placebo (ORs ranged from 0.31 [omarigliptin] to 2.31 [saxagliptin]; all CrIs crossed 1.0). Rankings suggested omarigliptin as most favorable, alogliptin/linagliptin/sitagliptin intermediate, and saxagliptin/teneligliptin least favorable. Baseline DR incidence moderated treatment effects; other prespecified covariates were not significant. MBNMAdose showed no dose-response relationship for DR.</div></div><div><h3>Conclusions</h3><div>Current randomized evidence indicates class-level neutrality of DPP-4 inhibitors on DR incidence, with no dose–response signal. Choice among gliptins may therefore be guided primarily by glycemic efficacy, safety, and participant characteristics rather than retinal risk.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109234"},"PeriodicalIF":3.1,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of small, dense lipoproteins in type-2 diabetes and maturity-onset diabetes of the young (MODY): What's new.","authors":"Aleksandra Zeljkovic, Jelena Vekic, Mohamed A Elrayess, Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109233","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109233","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":" ","pages":"109233"},"PeriodicalIF":3.1,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145634304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients","authors":"Qi Fan ,&nbsp;Guoqiang Qin ,&nbsp;Bingyu Du ,&nbsp;Mengfan Kan ,&nbsp;Mengyuan Li ,&nbsp;Qiu Li ,&nbsp;Zhongwen Zhang","doi":"10.1016/j.jdiacomp.2025.109236","DOIUrl":"10.1016/j.jdiacomp.2025.109236","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate the clinical efficacy and explore the potential mechanisms of novel mineralocorticoid receptor antagonists (MRAs) in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>Randomized controlled trials (RCTs), including relevant subgroup analyses, of steroidal MRAs (eplerenone, canrenone) and non-steroidal MRAs (finerenone, esaxerenone) in T2DM patients were identified through systematic searches of English and Chinese databases. Meta-analysis was performed to assess clinical outcomes, and network pharmacology was used to explore underlying molecular mechanisms.</div></div><div><h3>Result</h3><div>18 RCTs (including relevant subgroup analyses) involving 30,103 participants were included. MRAs significantly reduced MACE risk (OR = 0.81, 95 % CI: 0.75–0.86; <em>P</em> &lt; 0.00001). MRAs also significantly decreased cardiovascular mortality (OR = 0.86, 95 % CI: 0.77–0.97; <em>P</em> = 0.01) and hospitalization for heart failure (OR = 0.77, 95 % CI: 0.68–0.87; <em>P</em> &lt; 0.0001). Network pharmacology identified that steroidal MRAs mainly act via IL-17 and relaxin signaling pathways, targeting MAPK10, GSK3B, PTGS2, NOS2, and MMP1. Non-steroidal MRAs primarily modulate Ras and relaxin pathways, involving targets such as EGFR and PIK3C.</div></div><div><h3>Conclusions</h3><div>This study provides high-certainty evidence supporting MRAs in reducing MACE and heart failure hospitalization, and moderate-certainty evidence for benefits on cardiovascular mortality. Cardioprotective effects may involve Ras, IL-17, and relaxin signaling.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109236"},"PeriodicalIF":3.1,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current primary care approaches to diabetic foot prevention and treatment","authors":"Mahmoud Ibrahim ,&nbsp;Ebtesam M. Ba-Essa ,&nbsp;Asma Ahmed ,&nbsp;David G. Armstrong ,&nbsp;Mario Barmaki ,&nbsp;Avivit Cahn ,&nbsp;Kevin Cassar ,&nbsp;Omer Hamtzany ,&nbsp;José Luis Lázaro Martínez ,&nbsp;Helard Manrique ,&nbsp;Omar Mobarak ,&nbsp;Ashu Rastogi ,&nbsp;Manfredi Rizzo ,&nbsp;Shehla Shaikh ,&nbsp;Guillermo E. Umpierrez","doi":"10.1016/j.jdiacomp.2025.109231","DOIUrl":"10.1016/j.jdiacomp.2025.109231","url":null,"abstract":"<div><div>Diabetes-related foot disease is a significant source of morbidity and mortality among people with diabetes, affecting approximately 1.8 % of the global population and leading to many hospital admissions and non-traumatic amputations. Structured multidisciplinary care for the management of diabetes-related foot disease has been shown to reduce complication rates. The role of primary care providers is crucial in the education, recognition, management, and referral of people with diabetes-related foot disease. This evidence-based review article combines expert opinion with research-based consensus to offer comprehensive yet actionable guidance for primary care providers. It discusses the different domains of care for diabetes-related foot disease, including prevention, cardiometabolic biomarkers, education, risk stratification, complication detection, disease staging, treatment options, and management considerations for different geographic populations.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109231"},"PeriodicalIF":3.1,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regenerative medicine approaches for treating diabetes: Current advances and future directions","authors":"Sanja Medenica ,&nbsp;Dzihan Abazovic ,&nbsp;Jovana Vukovic ,&nbsp;Tanja Vojinovic ,&nbsp;Filip Tomovic ,&nbsp;Giuseppe Defeudis ,&nbsp;Rossella Mazzilli ,&nbsp;Zlata Kovacevic ,&nbsp;Dusan Djurdjic ,&nbsp;Vladimir Prelevic ,&nbsp;Tanja Abazovic ,&nbsp;Manfredi Rizzo ,&nbsp;Essam M. Abdelalim","doi":"10.1016/j.jdiacomp.2025.109232","DOIUrl":"10.1016/j.jdiacomp.2025.109232","url":null,"abstract":"<div><div>Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, has become a global health issue. The disease primarily presents as type 1 diabetes (T1D), caused by autoimmune β-cell destruction; type 2 diabetes (T2D), driven by insulin resistance and β-cell dysfunction; and monogenic diabetes, resulting from single-gene mutations affecting insulin production or β-cell function. Chronic hyperglycemia increases the risk of severe complications, including cardiovascular disease, neuropathy, and kidney failure. Despite advancements in insulin therapy and glucose monitoring, no cure currently exists for diabetes, with treatments mainly focused on managing symptoms rather than addressing the underlying β-cell loss. Regenerative medicine offers new hope, particularly through β-cell replacement strategies such as islet and stem cell-derived β-cell transplantation. Advances in generating hypoimmunogenic stem cell-derived pancreatic β-cells may help overcome immune rejection and donor shortages. These therapies have shown promise in clinical trials for both T1D and T2D. Furthermore, pharmacological strategies targeting β-cell regeneration show promise in enhancing β-cell proliferation and function. This review highlights the significant advancements in regenerative approaches for diabetes, underscoring the potential for long-term management and, ultimately, a cure for diabetes in the future.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109232"},"PeriodicalIF":3.1,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of a 12-week lifestyle intervention on incretin response during an oral glucose tolerance test in Latino youth with obesity and impaired glucose tolerance","authors":"Jared Rosenberg ,&nbsp;Allison Williams ,&nbsp;Anny Gano ,&nbsp;Molly M. Deak ,&nbsp;Gabriel Q. Shaibi ,&nbsp;Joon Young Kim","doi":"10.1016/j.jdiacomp.2025.109228","DOIUrl":"10.1016/j.jdiacomp.2025.109228","url":null,"abstract":"<div><div>Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the two incretin hormones, play an important pathophysiological role in glucose homeostasis with insulinotropic effects on the pancreatic β-cells. While two previous studies in youth have examined the effects of a lifestyle intervention on incretin concentrations, neither study focused on improvements in glycemic status or oral glucose tolerance test (OGTT)-derived biomarkers. Therefore, we aimed to examine changes in the incretin responses during an OGTT before and after a 12-week lifestyle intervention in Latino youth with obesity and impaired glucose tolerance (IGT). A total of 9 Latino youth with obesity and IGT underwent a two-hour OGTT with 30-min blood samples collected for the measurement of glucose, insulin, and incretin hormones before and after the lifestyle intervention (nutrition education and 180 min of moderate-vigorous exercise weekly for a total of 12 weeks). From pre- to post-intervention, a trend towards reduction was observed in the total GIP area under the curve (AUC) during the OGTT (5499.1 ± 715.3 vs. 4085.2 ± 389.5 pg/mL, <em>p</em> = 0.059), with no change in GLP-1. Moreover, BMI%, glucose AUC, and two-hour glucose concentrations were significantly reduced after the intervention. Our data suggest that a lifestyle intervention in Latino youth with obesity and IGT could influence incretin and glucose metabolism. Future studies should examine if the GIP response to a lifestyle intervention is mediated by baseline glycemic status.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109228"},"PeriodicalIF":3.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145604447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the PPARG rs1801282 polymorphism on weight reduction and metabolic syndrome outcomes in obese individuals undergoing a partial meal replacement hypocaloric diet","authors":"Daniel de Luis,&nbsp;Olatz Izaola,&nbsp;David Primo,&nbsp;Daniel Rico,&nbsp;Juan Jose López","doi":"10.1016/j.jdiacomp.2025.109209","DOIUrl":"10.1016/j.jdiacomp.2025.109209","url":null,"abstract":"<div><h3>Background and aims</h3><div>No studies to date have specifically evaluated the effect of the <em>rs1801282</em> polymorphism on body weight loss. This study evaluates the role of the PPARG <em>rs1801282</em> polymorphism in modulating body weight loss and cardiovascular risk factor improvements in response to a partial meal replacement (pMR) hypocaloric diet among Caucasian patients with obesity.</div></div><div><h3>Methods</h3><div>A total of 512 subjects with severe obesity, defined by a body mass index (BMI) exceeding 35 kg/m², were recruited for the study. Each participant was instructed to follow a pMR hypocaloric diet a 12-week intervention period. Throughout the trial, comprehensive assessments were performed, including anthropometric parameters (body weight, BMI, fat mass, and waist circumference), blood pressure, biochemical profiling (lipid concentrations, fasting insulin levels, and calculation of the homeostatic model assessment of insulin resistance (HOMA-IR)) and Metabolic syndrome (MS).</div></div><div><h3>Results</h3><div>The cohort included 107 individuals (20.9 %) homozygous for the CC allele, 203 individuals (39.6 %) heterozygous (CG), and 202 individuals (39.5 %) homozygous for the GG allele. BMI (−2.3 ± 0.3 kg/m² vs − 1.0 ± 0.1 kg/m² (p = 0.01)), body weight (−9.0 ± 1.1 kg vs − 3.8 ± 2.1 kg (p = 0.01)), fat mass (−8.1 ± 0.2 kg vs − 2.8 ± 0.2 kg (p = 0.01)), waist circumference (−6.8 ± 0.1 cm vs − 5.1 ± 0.1 cm (p = 0.01)), glucose levels (−15.1 ± 1.9 mg/dl vs − 4.1 ± 2.8 mg/dl, p = 0.01), insulin (−9.8 ± 1.3 UI/L vs − 3.7 ± 2.1 UI/L, p = 0.01), HOMA-IR (−2.2 ± 1.0 units vs − 0.60 ± 0.2 units, p = 0.01), CRP (−1.3 ± 0.1 mg/dl vs − 0.2 ± 0.2 mg/dl, p = 0.01), triglycerides (−24.1 ± 3.3 mg/dl vs − 4.1 ± 3.2 mg/dl, p = 0.01), total-cholesterol (−23.2 ± 1.1 mg/dl vs − 8.9 ± 1.2 mg/dl, p = 0.01), LDL-cholesterol (−17.2 ± 1.2 mg/dl vs − 5.7 ± 1.1 mg/dl, p = 0.01), and HDL-cholesterol (8.2 ± 0.3 mg/dl vs 2.3 ± 1.2 mg/dl, p = 0.01) modifications were better in non-G allele carriers. After intervention, the odds ratio (OR) of MS in non-carrier of G allele improved OR 0.39 (95 %CI: 0.24–0.63; p = 0.02).</div></div><div><h3>Conclusions</h3><div>This study shows that the PPARG rs1801282 polymorphism modulates the response to pMR in Caucasian patients with obesity, with G allele carriers displaying a less favourable improvement in body weight and metabolic parameters.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109209"},"PeriodicalIF":3.1,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of modifiable lifestyle and clinical factors with cognitive function in adults with type 2 diabetes","authors":"Anahita Golchin ,&nbsp;Karen C. Johnson ,&nbsp;Denise K. Houston ,&nbsp;Jose A. Luchsinger ,&nbsp;Kristen M. Beavers ,&nbsp;Alain G. Bertoni ,&nbsp;Haiying Chen ,&nbsp;Lynne Wagenknecht ,&nbsp;Mark A. Espeland ,&nbsp;for the Action for Health in Diabetes (Look AHEAD) Aging Study Group","doi":"10.1016/j.jdiacomp.2025.109227","DOIUrl":"10.1016/j.jdiacomp.2025.109227","url":null,"abstract":"<div><h3>Aims</h3><div>Type 2 diabetes and obesity accelerate cognitive decline. Maintaining salutary levels of multiple lifestyle and clinical risk factors might be expected to protect against this. We examined whether healthier levels of adiposity, cardiorespiratory fitness, physical activity, and diabetes control were associated with better cognitive functioning.</div></div><div><h3>Methods</h3><div>Data are from the Action for Health in Diabetes clinical trial of adults with type 2 diabetes and overweight or obesity. Standardized measures of body mass indices, percent body fat, objective and self-reported physical activity, cardiorespiratory fitness, and HbA1c were collected across 4 and 8 years. Associations between healthier versus less healthy levels (categorized based on ± one standard deviation from the cohort mean) of these measures with subsequent standardized (z-scores) assessments of cognitive function were assessed using linear regression.</div></div><div><h3>Results</h3><div>Among 3723 participants, high versus low cardiorespiratory fitness was associated with 0.08 to 0.13 standard deviation better global cognitive function, executive function, and attention (<em>p</em> &lt; 0.001). Lower versus high HbA1c was associated with 0.17 to 0.22 standard deviation better cognitive function for all domains (p &lt; 0.001). Associations that fitness and HbA1c had with cognitive function were independent and additive. No significant associations with cognitive function were found for physical activity or adiposity.</div></div><div><h3>Conclusions</h3><div>Maintaining greater cardiorespiratory fitness and better diabetes control may protect cognitive function in type 2 diabetes.</div></div><div><h3><span><span><strong>ClinicalTrials.gov</strong></span><svg><path></path></svg></span> <strong>Identifier</strong></h3><div><span><span>NCT00017953</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109227"},"PeriodicalIF":3.1,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145518129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00274-0","DOIUrl":"10.1016/S1056-8727(25)00274-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109221"},"PeriodicalIF":3.1,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of non-alcoholic fatty liver disease, pericoronary fat attenuation index and computed tomography-derived fractional flow reserve in diabetic patients with suspected coronary artery disease","authors":"Ruili Qin ,&nbsp;Changqin Jiang ,&nbsp;Mengnan Zhang ,&nbsp;Xueyan Hou ,&nbsp;Xiaoling Tao ,&nbsp;Shuang Pan ,&nbsp;Zhaoqian Wang","doi":"10.1016/j.jdiacomp.2025.109216","DOIUrl":"10.1016/j.jdiacomp.2025.109216","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to investigate the predictive value of non-alcoholic fatty liver disease (NAFLD), pericoronary fat attenuation index (FAI), and computed tomography-derived fractional flow reserve (CT-FFR) for major adverse cardiovascular events (MACE) in diabetic patients with suspected coronary artery disease.</div></div><div><h3>Methods</h3><div>This study retrospectively included 466 diabetic patients who underwent coronary computed tomography angiography (CCTA) and non-contrast chest CT from January 2017 to December 2018. The clinical data and imaging parameters of patients were collected. MACE was defined as rehospitalization for unstable angina, non-fatal myocardial infarction, late coronary revascularization, cardiac death, and all-cause mortality.</div></div><div><h3>Results</h3><div>During a median follow-up of 70 months, 76 patients experienced MACE. NAFLD (hazard ratio [HR] = 2.248; 95 % confidence interval [CI]: 1.362–3.710; <em>P</em> = 0.002), pericoronary FAI &gt; −71.42 HU (HR = 4.063; 95 % CI: 2.316–7.131; <em>P</em> &lt; 0.001), and CT-FFR ≤ 0.80 (HR = 6.023; 95 % CI: 2.567–14.132; <em>P</em> &lt; 0.001) associated with MACE independently. We developed six MACE prediction models: model 1: traditional clinical risk factors; model 2: model 1 + NAFLD; model 3: model 2 + CCTA characteristics; model 4: model 3 + CT-FFR ≤ 0.80; model 5: model 3 + pericoronary FAI &gt; −71.42 HU; model 6: model 5 + CT-FFR ≤ 0.80. The areas under curve of above six models were 0.698, 0.741, 0.861, 0.890, 0.917 and 0.936 respectively.</div></div><div><h3>Conclusions</h3><div>NAFLD, pericoronary FAI, and CT-FFR were independent predictors of MACE in diabetic patients. The multiparametric model 6 demonstrated the optimal predictive performance for MACE.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109216"},"PeriodicalIF":3.1,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}